Abstract: Systems, methods, and computer-readable storage media for a unified interface for querying data that may reside in one of a legacy database or a current database. Rather than performing a risky or potentially time-consuming database migration, new data is stored in the current database and the existing data remains in the legacy database. Users submit database queries through a query interface that hides or abstracts the complexity of the current and legacy databases from the users. Thus, while two separate databases exist on the back end, users do not know and do not need to know of that complexity when submitting a database query. The query interface can determine which database contains the requested data, convert the database query to the appropriate format, if necessary, for that database, and execute the converted query.

Abstract: Disclosed are systems, methods, and non-transitory computer-readable storage media for executing a database query based on an incomplete query. An example system configured to practice the method receives a web request, wherein a uniform resource locator (URL) of the web request provides an argument, and extracts the argument from the URL as a parameter for a database query. The system identifies an unspecified parameter in the database query, and selects a likely value for the unspecified parameter. Then the system executes the database query using the parameter and the likely value, and incorporates at least part of the query result in a web page served in response to the web request. The system can cache the web request and the likely value for the unspecified parameter for later use.

Abstract: A method and oligonucleotide compound for inhibiting replication of a nidovirus in virus-infected animal cells are disclosed. The compound (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the infected cells, (iii) contains between 8-25 nucleotide bases, and (iv) has a sequence capable of disrupting base pairing between the transcriptional regulatory sequences in the 5? leader region of the positive-strand viral genome and negative-strand 3? subgenomic region. In practicing the method, infected cells are exposed to the compound in an amount effective to inhibit viral replication.

Abstract: The technology disclosed relates to tracking performance and initiatives of employees and automatically and proactively providing personalized coaching based on each employee's performance. In particular, it relates to automatically issuing personalized performance enhancement insights to an employee by evaluating the employee's current performance against progress features and exception features through timely performance checks. The progress features indicate a progression of an individual across a work cycle and exception features indicate low or high performance of the individual during the work cycle. Thus the personalized performance enhancement insights are automatically awarded when the current performance of the employee evidences lags in progress, regression, or low or high performance.

Abstract: The technology disclosed relates to tracking performance and initiatives of employees and providing real-time recognition for their successes and contributions through customizable recognition awards. In particular, it relates to automatically awarding recognition awards to an employee by evaluating the employee's current performance against progress features and exception features. The progress features indicate a progression of an individual across a work cycle and exception features indicate high performance of the individual during the work cycle. Thus the recognition awards are automatically awarded when the current performance of the employee evidences accomplishment of milestones or high performance.

Abstract: A device, system, and method for passively sealing a vessel containing a fluid and for sampling the fluid without carry-over or cross-contamination between the fluid sampling device, the sealing septum, and the vessel contents. The device includes an actuated septum having a plurality of septum fingers, to passively seal the vessel, and an actuation device, to open the passive seal without carry-over or cross-contamination. Each of the plurality of septum fingers includes a corresponding rib portion. The actuation device can be an actuation ring having an annulus. The plurality of septum fingers and corresponding rib portions are disposed internal or substantially internal to the vessel, while the actuation device is disposed external to the vessel.

Abstract: A method of inhibiting replication of a flavivirus in animal cells, and an oligonucleotide compound for use in the method are disclosed. The oligonucleotide analog (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the cells, (iii) contains between 8-40 nucleotide bases, and (iv) has a sequence of at least 8 bases complementary to a region of the virus' positive strand RNA genome that includes at least a portion of SEQ ID NOS:1-4. Exposure of cells infected with a flavivirus to the analog is effective to form within the cells, a heteroduplex structure composed of the virus ssRNA and the oligonucleotide, characterized by a Tm of dissociation of at least 45° C., and having disrupted base pairing between the virus' 5? and 3? cyclization sequences.

Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Picornaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Enterovirus and/or Rhinovirus infection in a mammal. The antisense antiviral compounds are substantially uncharged, morpholino oligonucleotides have a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with viral RNA sequences within a 32 nucleotide region of the viral 5? untranslated region identified by SEQ ID NO:7.

Abstract: Featured are systems, devices and apparatuses for use in minimally invasive surgical, diagnostic or therapeutic methods and/or techniques, in particular methods and/or techniques for a mammalian throat. In particular embodiments, a dexterity apparatus including one or more dexterity devices is featured, where each of the dexterity devices comprises surgical tools and each is configured and arranged with end-tip dexterity for enhanced manipulation. A portion of the dexterity devices is snake like, which is re-configurable (i.e., can be bent) so as to in effect maneuver the surgical tool and put the tool in a desired position with respect to the surgical site. Another portion of the dexterity device includes the surgical tool thereby providing the capability of performing surgical actions such as sewing, gripping, soft tissue manipulation, cutting and suction of saliva, blood and other materials from the surgical site.

Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5? or 3? terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 25 bases of the 3? terminus of the positive sense cRNA and; and c) the 50 bases surrounding the AUG start codon of an influenza viral mRNA.

Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picornoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5?-terminal end 40 bases of the positive-sense RNA strand of the virus.

Abstract: A computer-implemented system for analyzing copyright right ownership of a media content containing one or more copyrighted works, comprising the steps of: receiving, by a controller having a CPU, a media content from a first user via a wide area network, the media content comprising a mix of copyrighted works; parsing the media content into a format recognizable by a fingerprinting analytical algorithm; determining by the controller using the fingerprinting analytical algorithm copyright ownership information in the received media content; monitoring by the controller a playing of a select length of the media content from the content storage device by a second user; and reporting to a system operated by a copyright licensing entity by the controller the copyright ownership information associated with the select length of the media content played by the second user.

Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Picornaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Enterovirus and/or Rhinovirus infection in a mammal. The antisense antiviral compounds are substantially uncharged, including partially positively charged, morpholino oligonucleotides have a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with viral RNA sequences within a 32 nucleotide region of the viral 5? untranslated region identified by SEQ ID NO:4.

Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the Ebola virus AUG start site region of VP24; ii) the Ebola virus AUG start site region of VP35; iii) the Marburg virus AUG start site region of VP24; or iv) the Marburg virus AUG start site region of NP.

Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picornoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5?-terminal end 40 bases of the positive-sense RNA strand of the virus.

Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picomoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5?-terminal end 40 bases of the positive-sense RNA strand of the virus.

Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the Ebola virus AUG start site region of VP24; ii) the Ebola virus AUG start site region of VP35; iii) the Marburg virus AUG start site region of VP24; or iv) the Marburg virus AUG start site region of NP.

Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the Ebola virus AUG start site region of VP24; ii) the Ebola virus AUG start site region of VP35; iii) the Marburg virus AUG start site region of VP24; or iv) the Marburg virus AUG start site region of NP.

Abstract: A method of inhibiting replication of a flavivirus in animal cells, and an oligonucleotide compound for use in the method are disclosed. The oligonucleotide analog (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the cells, (iii) contains between 8-40 nucleotide bases, and (iv) has a sequence of at least 8 bases complementary to a region of the virus' positive strand RNA genome that includes at least a portion of SEQ ID NOS:1-4. Exposure of cells infected with a flavivirus to the analog is effective to form within the cells, a heteroduplex structure composed of the virus ssRNA and the oligonucleotide, characterized by a Tm of dissociation of at least 45° C., and having disrupted base pairing between the virus' 5? and 3? cyclization sequences.

Abstract: A method of inhibiting replication of a flavivirus in animal cells, and an oligonucleotide compound for use in the method are disclosed. The oligonucleotide analog (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the cells, (iii) contains between 8-40 nucleotide bases, and (iv) has a sequence of at least 8 bases complementary to a region of the virus' positive strand RNA genome that includes at least a portion of SEQ ID NOS:1-4. Exposure of cells infected with a flavivirus to the analog is effective to form within the cells, a heteroduplex structure composed of the virus ssRNA and the oligonucleotide, characterized by a Tm of dissociation of at least 45° C., and having disrupted base pairing between the virus' 5? and 3? cyclization sequences.